{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:16:07Z","timestamp":1786986967575,"version":"build-2736575974"},"reference-count":124,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"vor","delay-in-days":57,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Biochemistry"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.clinbiochem.2024.110826","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T18:51:28Z","timestamp":1727722288000},"page":"110826","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["The changing landscape of autoantibody testing in myasthenia gravis in the setting of novel drug treatments"],"prefix":"10.1016","volume":"133-134","author":[{"given":"Ali","family":"Mousavi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6863-5614","authenticated-orcid":false,"given":"Hans","family":"Frykman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinbiochem.2024.110826_b0005","article-title":"An update on laboratory diagnosis in myasthenia gravis \u2606","author":"Oger","year":"2015","journal-title":"Published Online"},{"issue":"8","key":"10.1016\/j.clinbiochem.2024.110826_b0010","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s40265-022-01726-y","article-title":"Pharmacotherapy of generalized myasthenia gravis with special emphasis on newer biologicals","volume":"82","author":"Menon","year":"2022","journal-title":"Drugs"},{"issue":"11","key":"10.1016\/j.clinbiochem.2024.110826_b0015","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10112235","article-title":"Myasthenia gravis: Epidemiology, pathophysiology and clinical manifestations","volume":"10","author":"Dresser","year":"2021","journal-title":"J. Clin. Med."},{"issue":"6","key":"10.1016\/j.clinbiochem.2024.110826_b0020","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1136\/archdischild-2013-304788","article-title":"How common is childhood myasthenia? The UK incidence and prevalence of autoimmune and congenital myasthenia","volume":"99","author":"Parr","year":"2014","journal-title":"Arch. Dis. Child."},{"issue":"17","key":"10.1016\/j.clinbiochem.2024.110826_b0025","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1212\/WNL.0b013e318217e735","article-title":"Increasing incidence of myasthenia gravis among elderly in British Columbia","volume":"76","author":"Pakzad","year":"2011","journal-title":"Canada. Neurology."},{"issue":"5","key":"10.1016\/j.clinbiochem.2024.110826_b0030","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/ana.410140504","article-title":"Prognosis of ocular myasthenia","volume":"14","author":"Bever","year":"1983","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.clinbiochem.2024.110826_b0035","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat. Rev. Dis. Primers."},{"key":"10.1016\/j.clinbiochem.2024.110826_b0040","doi-asserted-by":"crossref","unstructured":"Kuks JBM. 2009 Clinical Presentation and Epidemiology of Myasthenia Gravis. In: Myasthenia Gravis and Related Disorders. Humana Press:79-94. doi:10.1007\/978-1-59745-156-7_5.","DOI":"10.1007\/978-1-59745-156-7_5"},{"issue":"2","key":"10.1016\/j.clinbiochem.2024.110826_b0045","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/qjmed\/hcn152","article-title":"Myasthenic crisis","volume":"102","author":"Chaudhuri","year":"2008","journal-title":"QJM"},{"key":"10.1016\/j.clinbiochem.2024.110826_b0050","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2020.00185","article-title":"Congenital myasthenic syndrome caused by a novel hemizygous CHAT mutation","volume":"8","author":"Zhang","year":"2020","journal-title":"Front. Pediatr."},{"issue":"11","key":"10.1016\/j.clinbiochem.2024.110826_b0055","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.3390\/jcm10112235","article-title":"myasthenia gravis: epidemiology, pathophysiology and clinical manifestations","volume":"10","author":"Dresser","year":"2021","journal-title":"J. Clin. Med."},{"issue":"11","key":"10.1016\/j.clinbiochem.2024.110826_b0060","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.1819","article-title":"Epidemiology of myasthenia gravis in Sweden 2006\u20132016","volume":"10","author":"Westerberg","year":"2020","journal-title":"Brain Behav."},{"issue":"2","key":"10.1016\/j.clinbiochem.2024.110826_b0065","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/mus.28006","article-title":"Incidence and prevalence of myasthenia gravis in the <scp>United States<\/scp> : a claims-based analysis","volume":"69","author":"Rodrigues","year":"2024","journal-title":"Muscle Nerve"},{"issue":"2","key":"10.1016\/j.clinbiochem.2024.110826_b0070","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1468-1331.2012.03850.x","article-title":"Late-onset myasthenia not on the increase: a nationwide register study in <scp>D<\/scp> enmark, 1996\u20132009","volume":"20","author":"Pedersen","year":"2013","journal-title":"Eur. J. Neurol."},{"issue":"5","key":"10.1016\/j.clinbiochem.2024.110826_b0075","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1212\/WNL.40.5.786","article-title":"The relationship of age to outcome in myasthenia gravis","volume":"40","author":"Donaldson","year":"1990","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.clinbiochem.2024.110826_b0080","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1007\/s00415-012-6478-6","article-title":"Characteristics of late-onset myasthenia gravis","volume":"259","author":"\u017divkovi\u0107","year":"2012","journal-title":"J. Neurol."},{"key":"10.1016\/j.clinbiochem.2024.110826_b0085","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00212","article-title":"Autoantibody specificities in myasthenia gravis; implications for improved diagnostics and therapeutics","volume":"11","author":"Lazaridis","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clinbiochem.2024.110826_b0090","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.596621","article-title":"Immunopathology of autoimmune myasthenia gravis: implications for improved testing algorithms and treatment strategies","volume":"11","author":"Frykman","year":"2020","journal-title":"Front. Neurol."},{"issue":"10","key":"10.1016\/j.clinbiochem.2024.110826_b0095","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/nri916","article-title":"Unravelling the pathogenesis of myasthenia gravis","volume":"2","author":"Vincent","year":"2002","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.clinbiochem.2024.110826_b0100","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/nyas.13592","article-title":"Serological and experimental studies in different forms of myasthenia gravis","volume":"1413","author":"Vincent","year":"2018","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.clinbiochem.2024.110826_b0105","unstructured":"Zisimopoulou P EPTJLKZVMR et al. A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis. J Autoimmun."},{"issue":"2","key":"10.1016\/j.clinbiochem.2024.110826_b0110","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/ana.22312","article-title":"Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis","volume":"69","author":"Higuchi","year":"2011","journal-title":"Ann. Neurol."},{"issue":"3","key":"10.1016\/j.clinbiochem.2024.110826_b0115","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/mus.26985","article-title":"Clinical features of LRP4\/agrin-antibody\u2013positive myasthenia gravis: a multicenter study","volume":"62","author":"Rivner","year":"2020","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.clinbiochem.2024.110826_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2022.577895","article-title":"LRP4-IgG service line testing in seronegative myasthenia gravis and controls","volume":"368","author":"Klein","year":"2022","journal-title":"J. Neuroimmunol."},{"issue":"23","key":"10.1016\/j.clinbiochem.2024.110826_b0125","doi-asserted-by":"crossref","first-page":"6717","DOI":"10.1046\/j.1432-1033.2000.01785.x","article-title":"Molecular targets for autoimmune and genetic disorders of neuromuscular transmission","volume":"267","author":"Vincent","year":"2000","journal-title":"Eur. J. Biochem."},{"issue":"10","key":"10.1016\/j.clinbiochem.2024.110826_b0130","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.clinbiochem.2024.110826_b0135","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1749-6632.1993.tb22936.x","article-title":"Seronegative myasthenia gravis: evidence for plasma factor(s) interfering with acetylcholine receptor functiona","volume":"681","author":"Vincent","year":"1993","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"4","key":"10.1016\/j.clinbiochem.2024.110826_b0140","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/ana.410300407","article-title":"Seronegative myasthenia gravis: a plasma factor inhibiting agonist-induced acetylcholine receptor function copurifies with IgM","volume":"30","author":"Yamamoto","year":"1991","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.clinbiochem.2024.110826_b0145","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.596621","article-title":"Immunopathology of autoimmune myasthenia gravis: implications for improved testing algorithms and treatment strategies","volume":"11","author":"Frykman","year":"2020","journal-title":"Front. Neurol."},{"issue":"4","key":"10.1016\/j.clinbiochem.2024.110826_b0150","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1093\/jalm\/jfaa199","article-title":"Laboratory testing of Myasthenia Gravis: New Treatments Drive Change","volume":"6","author":"Frykman","year":"2021","journal-title":"J. Appl. Lab. Med."},{"key":"10.1016\/j.clinbiochem.2024.110826_b0155","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2020.581097","article-title":"The structure, function, and physiology of the fetal and adult acetylcholine receptor in muscle","volume":"13","author":"Cetin","year":"2020","journal-title":"Front. Mol. Neurosci."},{"issue":"1\u20132","key":"10.1016\/j.clinbiochem.2024.110826_b0160","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s12031-009-9271-y","article-title":"Antigenic structure of the human muscle nicotinic acetylcholine receptor main immunogenic region","volume":"40","author":"Luo","year":"2010","journal-title":"J. Mol. Neurosci."},{"issue":"15","key":"10.1016\/j.clinbiochem.2024.110826_b0165","doi-asserted-by":"crossref","first-page":"3799","DOI":"10.1111\/j.1742-4658.2007.05935.x","article-title":"Muscle and neuronal nicotinic acetylcholine receptors","volume":"274","author":"Kalamida","year":"2007","journal-title":"FEBS J."},{"issue":"5","key":"10.1016\/j.clinbiochem.2024.110826_b0170","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1586\/eci.12.34","article-title":"Muscle autoantibodies in myasthenia gravis: beyond diagnosis?","volume":"8","author":"Meriggioli","year":"2012","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.clinbiochem.2024.110826_b0175","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1749-6632.1987.tb51301.x","article-title":"The membrane attack complex of complement at the endplate in myasthenia gravis","volume":"505","author":"Engel","year":"1987","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"1","key":"10.1016\/j.clinbiochem.2024.110826_b0180","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/nyas.13522","article-title":"Myasthenia gravis: the role of complement at the neuromuscular junction","volume":"1412","author":"Howard","year":"2018","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.clinbiochem.2024.110826_b0185","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1749-6632.1981.tb33730.x","article-title":"The immunopathology of acquired my asthenia gravis","volume":"377","author":"Engel","year":"1981","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"20","key":"10.1016\/j.clinbiochem.2024.110826_b0190","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJM197805182982004","article-title":"Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation","volume":"298","author":"Drachman","year":"1978","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clinbiochem.2024.110826_b0195","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1749-6632.1993.tb22891.x","article-title":"Effector mechanisms of myasthenic antibodies","volume":"681","author":"Richman","year":"1993","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"5","key":"10.1016\/j.clinbiochem.2024.110826_b0200","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/mus.24057","article-title":"Targeting therapy to the neuromuscular junction: Proof of concept","volume":"49","author":"Kusner","year":"2014","journal-title":"Muscle Nerve"},{"issue":"3","key":"10.1016\/j.clinbiochem.2024.110826_b0205","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/85520","article-title":"Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies","volume":"7","author":"Hoch","year":"2001","journal-title":"Nat. Med."},{"key":"10.1016\/j.clinbiochem.2024.110826_b0210","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaut.2016.11.005","article-title":"IgG4 autoantibodies against muscle-specific kinase undergo Fab-arm exchange in myasthenia gravis patients","volume":"77","author":"Koneczny","year":"2017","journal-title":"J. Autoimmun."},{"issue":"5","key":"10.1016\/j.clinbiochem.2024.110826_b0215","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.3390\/ijms22052455","article-title":"Secreted signaling molecules at the neuromuscular junction in physiology and pathology","volume":"22","author":"Ohkawara","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.clinbiochem.2024.110826_b0220","doi-asserted-by":"crossref","first-page":"13928","DOI":"10.1038\/srep13928","article-title":"Collagen Q and anti-MuSK autoantibody competitively suppress agrin\/LRP4\/MuSK signaling","volume":"5","author":"Otsuka","year":"2015","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.clinbiochem.2024.110826_b0225","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1001\/archneurol.2011.2393","article-title":"Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis","volume":"69","author":"Tzartos","year":"2012","journal-title":"Arch. Neurol."},{"issue":"6","key":"10.1016\/j.clinbiochem.2024.110826_b0230","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200147","article-title":"IgG1-3 MuSK antibodies inhibit AChR cluster formation, restored by SHP2 inhibitor, despite normal MuSK, DOK7, or AChR subunit phosphorylation","volume":"10","author":"Cao","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"10.1016\/j.clinbiochem.2024.110826_b0235","unstructured":"Hohlfeld R, WH. Reflections on the \u201cintrathymic pathogenesis\u201d of myasthenia gravis."},{"issue":"7","key":"10.1016\/j.clinbiochem.2024.110826_b0240","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1200\/JCO.1999.17.7.2280","article-title":"Thymoma: state of the art","volume":"17","author":"Thomas","year":"1999","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.clinbiochem.2024.110826_b0245","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3988\/jcn.2012.8.3.161","article-title":"Incidence of thymoma in myasthenia gravis: a systematic review","volume":"8","author":"Mao","year":"2012","journal-title":"Journal of Clinical Neurology."},{"issue":"1","key":"10.1016\/j.clinbiochem.2024.110826_b0250","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s00415-004-0278-6","article-title":"Myasthenia gravis: changes observed in a 30-years retrospective clinical study of a hospital-based population","volume":"251","author":"Potagas","year":"2004","journal-title":"J. Neurol."},{"key":"10.1016\/j.clinbiochem.2024.110826_b0255","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jneuroim.2008.05.020","article-title":"Reflections on the \u201cintrathymic pathogenesis\u201d of myasthenia gravis","volume":"201\u2013202","author":"Hohlfeld","year":"2008","journal-title":"J. Neuroimmunol."},{"issue":"1\u20132","key":"10.1016\/j.clinbiochem.2024.110826_b0260","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jns.2012.12.025","article-title":"Modeling the intrathymic pathogenesis of myasthenia gravis","volume":"333","author":"Levinson","year":"2013","journal-title":"J. Neurol. Sci."},{"issue":"1\u20132","key":"10.1016\/j.clinbiochem.2024.110826_b0265","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jneuroim.2003.11.013","article-title":"Thymic myoid cells express high levels of muscle genes","volume":"148","author":"Mesnard-Rouiller","year":"2004","journal-title":"J. Neuroimmunol."},{"issue":"7","key":"10.1016\/j.clinbiochem.2024.110826_b0270","doi-asserted-by":"crossref","first-page":"671","DOI":"10.3390\/cells8070671","article-title":"Myasthenia gravis: pathogenic effects of autoantibodies on neuromuscular architecture","volume":"8","author":"Koneczny","year":"2019","journal-title":"Cells."},{"issue":"7","key":"10.1016\/j.clinbiochem.2024.110826_b0275","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.4049\/jimmunol.171.7.3847","article-title":"Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia gravis","volume":"171","author":"T\u00fcz\u00fcn","year":"2003","journal-title":"J. Immunol."},{"issue":"11","key":"10.1016\/j.clinbiochem.2024.110826_b0280","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/s41582-020-0400-0","article-title":"Complement in neurological disorders and emerging complement-targeted therapeutics","volume":"16","author":"Dalakas","year":"2020","journal-title":"Nat. Rev. Neurol."},{"issue":"12","key":"10.1016\/j.clinbiochem.2024.110826_b0285","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2019-231296","article-title":"Importance of clinical tests in ocular myasthenia","volume":"12","author":"Saluja","year":"2019","journal-title":"BMJ Case Rep."},{"issue":"6","key":"10.1016\/j.clinbiochem.2024.110826_b0290","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1007\/s00415-022-10986-3","article-title":"Bedside and laboratory diagnostic testing in myasthenia","volume":"269","author":"Yoganathan","year":"2022","journal-title":"J. Neurol."},{"issue":"8","key":"10.1016\/j.clinbiochem.2024.110826_b0295","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1038\/s41433-018-0101-8","article-title":"Evaluating the temperature effects of ice and heat tests on ptosis due to Myasthenia Gravis","volume":"32","author":"Marinos","year":"2018","journal-title":"Eye"},{"key":"10.1016\/j.clinbiochem.2024.110826_b0300","unstructured":"Ropper A. H. SMAKJP, SPS. 2019 Disorders of the Neuromuscular Junction, Myotonias, and Persistent Muscle Fiber Activity. . Vol 11th ed. (Adams and Victor\u2019s, ed.). McGraw Hill \/ Medical. USA."},{"issue":"6","key":"10.1016\/j.clinbiochem.2024.110826_b0305","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s10072-019-03746-1","article-title":"Italian recommendations for the diagnosis and treatment of myasthenia gravis","volume":"40","author":"Evoli","year":"2019","journal-title":"Neurol. Sci."},{"issue":"4","key":"10.1016\/j.clinbiochem.2024.110826_b0310","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/ana.410120406","article-title":"Electrophysiological and clinical correlation in myasthenia gravis","volume":"12","author":"Oh","year":"1982","journal-title":"Ann. Neurol."},{"issue":"5","key":"10.1016\/j.clinbiochem.2024.110826_b0315","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.neucli.2018.01.003","article-title":"Repetitive nerve stimulation and jitter measurement with disposable concentric needle electrode in newly diagnosed myasthenia gravis patients","volume":"48","author":"Sirin","year":"2018","journal-title":"Neurophysiol. Clin."},{"issue":"7","key":"10.1016\/j.clinbiochem.2024.110826_b0320","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1016\/j.clinph.2008.03.008","article-title":"Concentric needle single fiber electromyography: comparative jitter on voluntary-activated and stimulated Extensor Digitorum Communis","volume":"119","author":"Kouyoumdjian","year":"2008","journal-title":"Clin. Neurophysiol."},{"issue":"3","key":"10.1016\/j.clinbiochem.2024.110826_b0325","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/mus.21424","article-title":"Jitter recordings with concentric needle electrodes","volume":"40","author":"St\u00e5lberg","year":"2009","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.clinbiochem.2024.110826_b0330","doi-asserted-by":"crossref","unstructured":"Crum BA, Harper CM. Single-Fiber Electromyography. In: Rubin DI, ed. Clinical Neurophysiology. Oxford University PressNew York; 2021:525-548. doi:10.1093\/med\/9780190067854.003.0027.","DOI":"10.1093\/med\/9780190067854.003.0027"},{"issue":"3","key":"10.1016\/j.clinbiochem.2024.110826_b0335","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/mus.24750","article-title":"Reference values for jitter recorded by concentric needle electrodes in healthy controls: a multicenter study","volume":"53","author":"St\u00e5lberg","year":"2016","journal-title":"Muscle Nerve"},{"issue":"2","key":"10.1016\/j.clinbiochem.2024.110826_b0340","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/mus.25214","article-title":"Repetitive nerve stimulation cutoff values for the diagnosis of myasthenia gravis","volume":"55","author":"Abraham","year":"2017","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.clinbiochem.2024.110826_b0345","doi-asserted-by":"crossref","unstructured":"Vahabi Z, Nazari F, Fatehi F, et al. 2021 Electrophysiological studies in patients with seropositive\/seronegative myasthenia gravis. Curr J Neurol. Published online November 7. doi:10.18502\/cjn.v20i3.7686.","DOI":"10.18502\/cjn.v20i3.7686"},{"issue":"3","key":"10.1016\/j.clinbiochem.2024.110826_b0350","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/01.cnd.0000155026.66153.f0","article-title":"A comparison of electrodiagnostic tests in ocular myasthenia gravis","volume":"6","author":"Katzberg","year":"2005","journal-title":"J. Clin. Neuromuscul. Dis."},{"issue":"8","key":"10.1016\/j.clinbiochem.2024.110826_b0355","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.3390\/jcm10081736","article-title":"Diagnosis of myasthenia gravis","volume":"10","author":"Rousseff","year":"2021","journal-title":"J. Clin. Med."},{"issue":"11","key":"10.1016\/j.clinbiochem.2024.110826_b0360","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.5692\/clinicalneurol.52.1312","article-title":"New clinical entity of myasthenia gravis with autoimmune targets of heart and skeletal muscles","volume":"52","author":"Suzuki","year":"2012","journal-title":"Rinsho Shinkeigaku"},{"key":"10.1016\/j.clinbiochem.2024.110826_b0365","unstructured":"Beeson D JLNDJVA. A transfected human muscle cell line expressing the adult subtype of the human muscle acetylcholine receptor for diagnostic assays in myasthenia gravis."},{"issue":"12","key":"10.1016\/j.clinbiochem.2024.110826_b0370","doi-asserted-by":"crossref","first-page":"3334","DOI":"10.1073\/pnas.70.12.3334","article-title":"Studies on purified eel acetylcholine receptor and anti-acetylcholine receptor antibody","volume":"70","author":"Patrick","year":"1973","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"3","key":"10.1016\/j.clinbiochem.2024.110826_b0375","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/0891693031000094935","article-title":"Frequency of anti-AChR \u220a subunit-specific antibodies in MG","volume":"36","author":"Ohta","year":"2003","journal-title":"Autoimmunity"},{"issue":"22","key":"10.1016\/j.clinbiochem.2024.110826_b0380","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000010910","article-title":"Improving accuracy of myasthenia gravis autoantibody testing by reflex algorithm","volume":"95","author":"Shelly","year":"2020","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.clinbiochem.2024.110826_b0385","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/j.1749-6632.1987.tb51321.x","article-title":"Clinical correlations of antibodies that bind, block, or modulate human acetylcholine receptors in myasthenia gravis","volume":"505","author":"Howard","year":"1987","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"2","key":"10.1016\/j.clinbiochem.2024.110826_b0390","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1309\/AJCPYEOR6SGE8ZLU","article-title":"Detection of acetylcholine receptor modulating antibodies by flow cytometry","volume":"143","author":"Lozier","year":"2015","journal-title":"Am. J. Clin. Pathol."},{"issue":"5","key":"10.1016\/j.clinbiochem.2024.110826_b0395","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/mus.21653","article-title":"Eliminating false-positive results in serum tests for neuromuscular autoimmunity","volume":"41","author":"Apiwattanakul","year":"2010","journal-title":"Muscle Nerve"},{"issue":"5","key":"10.1016\/j.clinbiochem.2024.110826_b0400","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1080\/01676830.2017.1423350","article-title":"False positive acetylcholine receptor antibodies in a case of unilateral chronic progressive external ophthalmoplegia: case report and review of literature","volume":"37","author":"Rajput","year":"2018","journal-title":"Orbit (London)."},{"issue":"6","key":"10.1016\/j.clinbiochem.2024.110826_b0405","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/ene.13300","article-title":"Multiple antibody detection in \u2018seronegative\u2019 myasthenia gravis patients","volume":"24","author":"Hong","year":"2017","journal-title":"Eur. J. Neurol."},{"issue":"7","key":"10.1016\/j.clinbiochem.2024.110826_b0410","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1093\/brain\/awn092","article-title":"IgG1 antibodies to acetylcholine receptors in \u2018seronegative\u2019 myasthenia gravis\u2020","volume":"131","author":"Leite","year":"2008","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.clinbiochem.2024.110826_b0415","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1749-6632.2012.06833.x","article-title":"The search for new antigenic targets in myasthenia gravis","volume":"1275","author":"Cossins","year":"2012","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.clinbiochem.2024.110826_b0420","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.120084","article-title":"Comparison of fixed cell-based assay to radioimmunoprecipitation assay for acetylcholine receptor antibody detection in myasthenia gravis","volume":"432","author":"Mirian","year":"2022","journal-title":"J. Neurol. Sci."},{"issue":"1","key":"10.1016\/j.clinbiochem.2024.110826_b0425","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200038","article-title":"Comparison of fixed and live cell-based assay for the detection of AChR and MuSK antibodies in myasthenia gravis","volume":"10","author":"Spagni","year":"2023","journal-title":"Neurology - Neuroimmunology Neuroinflammation."},{"key":"10.1016\/j.clinbiochem.2024.110826_b0430","first-page":"38","article-title":"A multicentre, prospective, double-blind study comparing the accuracy of autoantibody diagnostic assays in myasthenia gravis: the SCREAM study","author":"Li","year":"2023","journal-title":"Lancet Reg Health West Pac."},{"issue":"1","key":"10.1016\/j.clinbiochem.2024.110826_b0435","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1038\/s41467-023-37083-x","article-title":"Affinity maturation generates pathogenic antibodies with dual reactivity to DNase1L3 and dsDNA in systemic lupus erythematosus","volume":"14","author":"Gomez-Ba\u00f1uelos","year":"2023","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.clinbiochem.2024.110826_b0440","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/ncprheum0895","article-title":"Nature and functions of autoantibodies","volume":"4","author":"Elkon","year":"2008","journal-title":"Nat. Clin. Pract. Rheumatol."},{"key":"10.1016\/j.clinbiochem.2024.110826_b0445","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.00603","article-title":"Mechanisms of autoantibody-induced pathology","volume":"8","author":"Ludwig","year":"2017","journal-title":"Front. Immunol."},{"issue":"15_supplement","key":"10.1016\/j.clinbiochem.2024.110826_b0450","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.94.15_supplement.5239","article-title":"Validation of live clustered cell based acethylcholine antibody assay and utility in children with myasthenia gravis (5239)","volume":"94","author":"Frykman","year":"2020","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.clinbiochem.2024.110826_b0455","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/cyto.b.20454","article-title":"A rapid, fluorescence-based assay for detecting antigenic modulation of the acetylcholine receptor on human cell lines","volume":"76B","author":"Keefe","year":"2009","journal-title":"Cytometry B Clin. Cytom."},{"issue":"1","key":"10.1016\/j.clinbiochem.2024.110826_b0460","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000116785","article-title":"Long-term results of corticosteroid therapy in patients with myasthenia gravis","volume":"32","author":"Evoli","year":"1992","journal-title":"Eur. Neurol."},{"issue":"1","key":"10.1016\/j.clinbiochem.2024.110826_b0465","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/nyas.13518","article-title":"Myasthenia gravis with antibodies to MuSK: an update","volume":"1412","author":"Evoli","year":"2018","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"6","key":"10.1016\/j.clinbiochem.2024.110826_b0470","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1212\/WNL.47.6.1552","article-title":"A transfected human muscle cell line expressing the adult subtype of the human muscle acetylcholine receptor for diagnostic assays in myasthenia gravis","volume":"47","author":"Beeson","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.clinbiochem.2024.110826_b0475","unstructured":"Evoli A APDVIRPCBEMM. Myasthenia gravis with antibodies to MuSK: an update. ."},{"issue":"3","key":"10.1016\/j.clinbiochem.2024.110826_b0480","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1007\/s00415-022-11458-4","article-title":"Clinical pitfalls and serological diagnostics of MuSK myasthenia gravis","volume":"270","author":"Kwon","year":"2023","journal-title":"J. Neurol."},{"key":"10.1016\/j.clinbiochem.2024.110826_b0485","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00776","article-title":"Autoimmune pathology in myasthenia gravis disease subtypes is governed by divergent mechanisms of immunopathology","volume":"11","author":"Fichtner","year":"2020","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.clinbiochem.2024.110826_b0490","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1212\/01.wnl.0000228225.23349.5d","article-title":"Anti-MuSK antibodies: correlation with myasthenia gravis severity","volume":"67","author":"Bartoccioni","year":"2006","journal-title":"Neurology"},{"issue":"1\u20132","key":"10.1016\/j.clinbiochem.2024.110826_b0495","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jneuroim.2008.01.013","article-title":"Clinical fluctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1","volume":"195","author":"Niks","year":"2008","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.clinbiochem.2024.110826_b0500","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1212757","article-title":"Immunotherapies in MuSK-positive myasthenia gravis; an IgG4 antibody-mediated disease","volume":"14","author":"Vakrakou","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clinbiochem.2024.110826_b0505","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jaut.2013.12.004","article-title":"A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis","volume":"52","author":"Zisimopoulou","year":"2014","journal-title":"J. Autoimmun."},{"issue":"3","key":"10.1016\/j.clinbiochem.2024.110826_b0510","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/mus.25438","article-title":"Agrin and low-density lipoprotein-related receptor protein 4 antibodies in amyotrophic lateral sclerosis patients","volume":"55","author":"Rivner","year":"2017","journal-title":"Muscle Nerve"},{"issue":"6","key":"10.1016\/j.clinbiochem.2024.110826_b0515","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s00415-017-8514-z","article-title":"Screening for lipoprotein receptor-related protein 4-, agrin-, and titin-antibodies and exploring the autoimmune spectrum in myasthenia gravis","volume":"264","author":"Cordts","year":"2017","journal-title":"J. Neurol."},{"key":"10.1016\/j.clinbiochem.2024.110826_b0520","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jneuroim.2015.04.015","article-title":"MuSK autoantibodies in myasthenia gravis detected by cell based assay \u2014 a multinational study","volume":"284","author":"Tsonis","year":"2015","journal-title":"J. Neuroimmunol."},{"issue":"10","key":"10.1016\/j.clinbiochem.2024.110826_b0525","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000012463","article-title":"Characterization of LRP4\/agrin antibodies from a patient with myasthenia gravis","volume":"97","author":"Yu","year":"2021","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.clinbiochem.2024.110826_b0530","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200220","article-title":"Functional signature of LRP4 antibodies in myasthenia gravis","volume":"11","author":"Chuquisana","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"23","key":"10.1016\/j.clinbiochem.2024.110826_b0535","doi-asserted-by":"crossref","first-page":"3749","DOI":"10.1016\/j.febslet.2013.10.001","article-title":"Mesdc2 plays a key role in cell-surface expression of Lrp4 and postsynaptic specialization in myotubes","volume":"587","author":"Hoshi","year":"2013","journal-title":"FEBS Lett."},{"key":"10.1016\/j.clinbiochem.2024.110826_b0540","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2022.577895","article-title":"LRP4-IgG service line testing in seronegative myasthenia gravis and controls","volume":"368","author":"Klein","year":"2022","journal-title":"J. Neuroimmunol."},{"issue":"2","key":"10.1016\/j.clinbiochem.2024.110826_b0545","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/acn3.26","article-title":"<scp>LRP<\/scp> 4 antibodies in serum and <scp>CSF<\/scp> from amyotrophic lateral sclerosis patients","volume":"1","author":"Tzartos","year":"2014","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.clinbiochem.2024.110826_b0550","doi-asserted-by":"crossref","unstructured":"Mehndiratta MM, Pandey S, Kuntzer T. 2014 Acetylcholinesterase inhibitor treatment for myasthenia gravis. Cochrane Database of Systematic Reviews. Published online October 13. doi:10.1002\/14651858.CD006986.pub3.","DOI":"10.1002\/14651858.CD006986.pub3"},{"issue":"6","key":"10.1016\/j.clinbiochem.2024.110826_b0555","article-title":"Corticosteroids for myasthenia gravis","volume":"2011","author":"Schneider-Gold","year":"2005","journal-title":"Cochrane Database Syst. Rev."},{"issue":"5","key":"10.1016\/j.clinbiochem.2024.110826_b0560","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/mus.21640","article-title":"Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: outcomes in 102 patients","volume":"41","author":"Hehir","year":"2010","journal-title":"Muscle Nerve"},{"issue":"3","key":"10.1016\/j.clinbiochem.2024.110826_b0565","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for management of myasthenia gravis","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"issue":"21","key":"10.1016\/j.clinbiochem.2024.110826_b0570","doi-asserted-by":"crossref","first-page":"6394","DOI":"10.3390\/jcm11216394","article-title":"New targeted agents in myasthenia gravis and future therapeutic strategies","volume":"11","author":"S\u00e1nchez-Tejerina","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.clinbiochem.2024.110826_b0575","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2147\/ITT.S377056","article-title":"Novel immunotherapies for myasthenia gravis","volume":"12","author":"Nair","year":"2023","journal-title":"Immunotargets Ther."},{"issue":"1","key":"10.1016\/j.clinbiochem.2024.110826_b0580","doi-asserted-by":"crossref","first-page":"e000241","DOI":"10.1136\/bmjmed-2022-000241","article-title":"New and emerging treatments for myasthenia gravis","volume":"2","author":"DeHart-McCoyle","year":"2023","journal-title":"BMJ Medicine."},{"issue":"12","key":"10.1016\/j.clinbiochem.2024.110826_b0585","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol."},{"issue":"12","key":"10.1016\/j.clinbiochem.2024.110826_b0590","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aax9586","article-title":"Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG immune complex\u2013mediated immune responses","volume":"5","author":"Blumberg","year":"2019","journal-title":"Sci. Adv."},{"issue":"1","key":"10.1016\/j.clinbiochem.2024.110826_b0595","doi-asserted-by":"crossref","DOI":"10.1016\/j.tmrv.2023.150767","article-title":"Therapeutic plasma exchange versus FcRn inhibition in autoimmune disease","volume":"38","author":"Mina-Osorio","year":"2024","journal-title":"Transfus. Med. Rev."},{"issue":"10","key":"10.1016\/j.clinbiochem.2024.110826_b0600","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/s41582-021-00547-z","article-title":"Getting specific: targeting Fc receptors in myasthenia gravis","volume":"17","author":"L\u00fcnemann","year":"2021","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.clinbiochem.2024.110826_b0605","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.118074","article-title":"IgG regulation through FcRn blocking: a novel mechanism for the treatment of myasthenia gravis","volume":"430","author":"Wolfe","year":"2021","journal-title":"J. Neurol. Sci."},{"issue":"10","key":"10.1016\/j.clinbiochem.2024.110826_b0610","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J. Clin. Investig."},{"issue":"6","key":"10.1016\/j.clinbiochem.2024.110826_b0615","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jamaneurol.2016.0113","article-title":"Myasthenia gravis treated with autologous hematopoietic stem cell transplantation","volume":"73","author":"Bryant","year":"2016","journal-title":"JAMA Neurol."},{"issue":"2","key":"10.1016\/j.clinbiochem.2024.110826_b0620","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/mus.20950","article-title":"Lifetime course of myasthenia gravis","volume":"37","author":"Grob","year":"2008","journal-title":"Muscle Nerve"}],"container-title":["Clinical Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912024001206?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912024001206?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,26]],"date-time":"2025-01-26T23:53:56Z","timestamp":1737935636000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009912024001206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":124,"alternative-id":["S0009912024001206"],"URL":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2024.110826","relation":{},"ISSN":["0009-9120"],"issn-type":[{"value":"0009-9120","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The changing landscape of autoantibody testing in myasthenia gravis in the setting of novel drug treatments","name":"articletitle","label":"Article Title"},{"value":"Clinical Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2024.110826","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of The Canadian Society of Clinical Chemists.","name":"copyright","label":"Copyright"}],"article-number":"110826"}}